Pre-treating human stem cells with low-dose bacterial endotoxin dramatically increased their production of antimicrobial peptides LL-37 and HBD-2, creating more effective wound-healing secretions that killed bacteria and accelerated healing in infected wounds.
LL-37 and HBD-2 markedly upregulatedLow-dose LPS preconditioning at 500 ng/mL enhanced antimicrobial peptide production in stem cell secretions, leading to improved bacterial killing and accelerated infected wound healing in vivo
What the researchers found
LPS preconditioning at 10-500 ng/mL enhanced hADSC proliferation (maximal at 500 ng/mL) without increasing apoptosis. It markedly upregulated antimicrobial peptides LL-37 and HBD-2, improving S. aureus and E. coli inhibition. In vivo, 500 ng/mL LPS-conditioned medium accelerated infected wound healing, increased collagen deposition, and reduced iNOS expression.
Why it matters
Chronically infected wounds affect millions of patients, especially those with diabetes and poor circulation. Enhancing stem cells' antimicrobial peptide production through simple preconditioning could create more effective cell-based wound treatments.
The numbers in context
10-500 ng/mL LPS range; 500 ng/mL optimal; LL-37 and HBD-2 upregulated; S. aureus and E. coli inhibited; iNOS downregulated in vivo
How the study worked
Human ADSCs were pretreated with LPS at various concentrations. Proliferation and apoptosis were assessed. Conditioned medium was tested for antimicrobial peptide expression (LL-37, HBD-2) and bacterial growth inhibition against S. aureus and E. coli. In vivo wound healing was evaluated in an infected wound model measuring healing rate, collagen deposition, and inflammation markers.
What this study cannot tell us
Preclinical study — human clinical validation needed. The LPS preconditioning approach introduces a bacterial product that could raise safety concerns. Only two bacterial species tested. The in vivo model details and animal numbers are not specified. Long-term safety of LPS-preconditioned stem cell therapy is unknown.
How to read the evidence
Preclinical study with both in vitro (cell culture, antimicrobial assays) and in vivo (wound healing model) validation. The combination of cellular, microbiological, and animal model data provides a thorough preclinical evidence package, though clinical translation requires human trials.
When this study was published
Published in 2026, this study represents current research at the intersection of stem cell therapy and antimicrobial peptide biology for wound healing applications.
The bigger picture
LL-37 (cathelicidin) and HBD-2 (human beta-defensin 2) are among the body's most important natural antibiotics. Finding that stem cells can be 'trained' to produce more of these peptides through simple preconditioning opens a new approach to cell-based wound therapy. Rather than adding external antibiotics (which promotes resistance), this strategy harnesses the body's own antimicrobial peptide arsenal. It aligns with the broader trend toward 'primed' or 'educated' cell therapies that perform specific functions more effectively than naive cells.
Questions still open
- Could the LPS preconditioning approach be adapted for clinical-grade stem cell manufacturing?
- Does the enhanced antimicrobial peptide production persist after transplantation into wounds, or is it a transient effect?
- Would this approach work against antibiotic-resistant bacteria like MRSA?
Common questions
What are LL-37 and HBD-2?
Why use stem cell secretions instead of the peptides directly?
Read the original research
Low-dose lipopolysaccharide pretreatment enhanced the proliferation and antibacterial activity of human adipose-derived mesenchymal stem cells.
Regenerative therapy, 31, 101057
Citation
Li, Linling; Diao, Jielin; Wang, Feng; Wang, Xia; Liu, Yicai; Fu, Xiaoming. (2026). Low-dose lipopolysaccharide pretreatment enhanced the proliferation and antibacterial activity of human adipose-derived mesenchymal stem cells.. Regenerative therapy, 31, 101057. https://doi.org/10.1016/j.reth.2025.101057